CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Short Interest Jumps 136.4%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 3,450,760 shares, an increase of 136.4% from the September 30th total of 1,459,951 shares. Based on an average daily volume of 342,939 shares, the short-interest ratio is currently 10.1 days. Approximately 7.0% of the shares of the stock are short sold.

CAMP4 Therapeutics Stock Up 1.5%

Shares of CAMP stock traded up $0.06 during mid-day trading on Friday, hitting $3.96. 137,718 shares of the company’s stock were exchanged, compared to its average volume of 211,979. CAMP4 Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $7.75. The stock has a 50-day simple moving average of $3.89 and a two-hundred day simple moving average of $4.24. The stock has a market cap of $248.50 million, a price-to-earnings ratio of -1.71 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, analysts anticipate that CAMP4 Therapeutics will post -0.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 400,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard A. Young bought 16,378 shares of the stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the acquisition, the director owned 186,388 shares in the company, valued at $307,540.20. The trade was a 9.63% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. Insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter worth approximately $78,000. Deutsche Bank AG purchased a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $138,000. Bank of New York Mellon Corp purchased a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $365,000. SummitTX Capital L.P. acquired a new position in CAMP4 Therapeutics during the first quarter worth approximately $1,497,000. Finally, BlackRock Inc. acquired a new position in CAMP4 Therapeutics during the second quarter worth approximately $7,185,000.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Chardan Capital decreased their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Piper Sandler restated an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Oppenheimer started coverage on shares of CAMP4 Therapeutics in a research note on Monday, October 5th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Raymond James Financial started coverage on shares of CAMP4 Therapeutics in a report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.44.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.